Absci
Absci is a clinical-stage drug developer using artificial intelligence to design its own antibody medicines, led by a hair-loss and endometriosis candidate, placing it among third-order compute beneficiaries that consume AI processing indirectly.
Revised after a check against the company's own annual filing.
Latest disclosed
10-Q filed 2026-08-11 · period ending 2026-06-30
Pieces naming this company
None yet.
No price is shown: the Index is a map of what each company sells and where it sits, not a quote board.